Ceftaroline: Difference between revisions
From IDWiki
(Created page with "== Background == === Mechanism of Action === * Binds to and inhibits PBP-2a === Spectrum of Activity === * Active against MRSA, Staphylococcus epidermidis, aerobic...") |
No edit summary |
||
| Line 1: | Line 1: | ||
== |
==Background== |
||
=== |
===Mechanism of Action=== |
||
* |
*Binds to and inhibits PBP-2a |
||
=== |
===Spectrum of Activity=== |
||
* |
*Active against [[MRSA]], [[Staphylococcus epidermidis]], aerobic Gram-negative bacilli (similar to [[ceftriaxone]]) |
||
* |
*Low to moderate activity against [[Enterococcus species]] |
||
* |
*Not active against [[Pseudomonas species]], ESBL-producers, or AmpC-producers |
||
=== Pharmacokinetics and Pharmacodynamics === |
|||
== Dosing == |
|||
* Crosses in CSF adequately |
|||
| ⚫ | |||
| ⚫ | |||
== |
==Dosing== |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
==Safety== |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
[[Category:Cephalosporins]] |
[[Category:Cephalosporins]] |
||
Revision as of 14:07, 12 September 2020
Background
Mechanism of Action
- Binds to and inhibits PBP-2a
Spectrum of Activity
- Active against MRSA, Staphylococcus epidermidis, aerobic Gram-negative bacilli (similar to ceftriaxone)
- Low to moderate activity against Enterococcus species
- Not active against Pseudomonas species, ESBL-producers, or AmpC-producers
Pharmacokinetics and Pharmacodynamics
- Crosses in CSF adequately
Dosing
- SSTI: ceftaroline 600 mg IV q12h
- Pneumonia and bacteremia: ceftaroline 600 mg IV q8h
Safety
Adverse Drug Reactions
- Rash, eosinophilia, reversible neutropenia (20% when ≥3 weeks)
